Pharvaris N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHVS research report →
Range $42 – $75
Price Chart
About the company
Pharvaris N. V. , a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
- CEO
- Berndt Modig
- IPO
- 2021
- Employees
- 148
- HQ
- Zug, ZH, CH
Get TickerSpark's AI analysis on PHVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.14B
- P/E
- -10.08
- Fwd P/E
- 18.02
- PEG
- -0.78
- P/S
- 0.00
- P/B
- 6.16
- EV/EBITDA
- -9.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.24%
- ROIC
- -60.72%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-169,822,932
- Net Income
- $-175,699,397-30.9%
- EPS
- $-2.97-19.8%
- OCF Growth
- -14.1%
- FCF Growth
- -13.7%
- 52W High
- $43.25
- 52W Low
- $20.65
- 50D MA
- $34.95
- 200D MA
- $30.48
- Beta
- -2.32
- RSI (14)
- 29
- Avg Volume
- 743.96K
No earnings-call transcripts are available for PHVS yet.
- Free Float
- 47.5%
- Shares Outstanding
- 69.88M
- Float Shares
- 33.19M
of shares held by institutions
112 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 6.57M | ▲ 280.80K |
| General Atlantic, L.P. | 6.55M | ▼ 1.48M |
| Foresite Capital Management Iv, LLC | 4.78M | 0 |
| Venbio Partners LLC | 4.64M | ▲ 4.13K |
| Viking Global Investors LP | 3.65M | 0 |
| Eqt Fund Management S.A R.L. | 3.42M | 0 |
| Deerfield Management Company, L.P. (Series C) | 3.38M | ▲ 250.00K |
| Bain Capital Life Sciences Investors, LLC | 2.68M | 0 |
| Wellington Management Group Llp | 2.39M | ▲ 274.03K |
| Polar Capital Holdings PLC | 2.33M | ▲ 1.55M |
| Point72 Asset Management, L.P. | 1.64M | ▲ 634.18K |
| Commodore Capital LP | 1.43M | ▼ 493.97K |
Held by 113 ETFs
Biggest fund positions in PHVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Monges Viviane | other | 11,969 |
| Sep 23, 26 | Monges Viviane | other | 11,969 |
| Sep 23, 26 | Monges Viviane | sell | 11,969 |
| Sep 22, 26 | Lu Peng | other | 45,308 |
| Sep 22, 26 | Lu Peng | other | 45,308 |
| Sep 22, 26 | Schikan Johannes Gerardus Christiaan Petrus | other | 800 |
| Sep 22, 26 | Schikan Johannes Gerardus Christiaan Petrus | sell | 800 |
| Sep 22, 26 | Schikan Johannes Gerardus Christiaan Petrus | other | 800 |
| Sep 21, 26 | Nassif David W. | sell | 6,000 |
| Sep 21, 26 | Nassif David W. | other | 500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PHVS coverage
Recent articles, reports, and earnings notes.
No research on PHVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHVS report →Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
globenewswire.com · Oct 5
Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock
defenseworld.net · Sep 22
Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares
defenseworld.net · Sep 22
Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock
defenseworld.net · Sep 16
Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC
defenseworld.net · Sep 16
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
zacks.com · Sep 15
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
seekingalpha.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.